RightFit Trial Directory

Breast Cancer clinical trials in New Brunswick, NJ

15 recruiting breast cancer studies with a site in New Brunswick, NJ.

All trials in New Brunswick, NJ · All Breast Cancer trials

RecruitingPhase 3NCT07391774

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Sponsor: National Cancer Institute (NCI)

Cherry Hill, NJ · New Brunswick, NJ · Sewell, NJ · +200 more sites

RecruitingPhase 3NCT06982521

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Sponsor: Relay Therapeutics, Inc.

Hackensack, NJ · New Brunswick, NJ · +50 more sites

RecruitingPhase 1NCT05877599

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Sponsor: AstraZeneca

New Brunswick, NJ · +19 more sites

RecruitingNot applicableNCT07214532

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Sponsor: Natera, Inc.

Camden, NJ · New Brunswick, NJ · +47 more sites

RecruitingPhase 1 / Phase 2NCT07488676

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Sponsor: Astellas Pharma Global Development, Inc.

Hackensack, NJ · New Brunswick, NJ · +16 more sites

RecruitingPhase 3NCT06492616

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Sponsor: Stemline Therapeutics, Inc.

Camden, NJ · Florham Park, NJ · Hackensack, NJ · +173 more sites

RecruitingPhase 3NCT05879926

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Sponsor: NRG Oncology

Camden, NJ · Cherry Hill, NJ · Elizabeth, NJ · +1223 more sites

RecruitingPhase 3NCT05812807

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Sponsor: Alliance for Clinical Trials in Oncology

Camden, NJ · Cherry Hill, NJ · Elizabeth, NJ · +825 more sites

RecruitingPhase 2NCT05467891

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

Sponsor: Oana Danciu

New Brunswick, NJ · +20 more sites

RecruitingPhase 3NCT05696626

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Sponsor: LeonaBio

Belleville, NJ · New Brunswick, NJ · +34 more sites

RecruitingPhase 3NCT06435429

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Sponsor: Jazz Pharmaceuticals

Hackensack, NJ · New Brunswick, NJ · +46 more sites

RecruitingPhase 2NCT05559164

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

Sponsor: Rutgers, The State University of New Jersey

Elizabeth, NJ · Hamilton, NJ · Jersey City, NJ · +7 more sites

RecruitingPhase 1NCT06139107

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Sponsor: Mridula George, MD

Belleville, NJ · Livingston, NJ · New Brunswick, NJ · +1 more sites

RecruitingPhase 4NCT07158164

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

Sponsor: Rutgers, The State University of New Jersey

Belleville, NJ · Elizabeth, NJ · Hamilton, NJ · +9 more sites

RecruitingPhase 1NCT05216432

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Sponsor: Relay Therapeutics, Inc.

New Brunswick, NJ · +23 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.